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Abstract: Hepatitis B virus (HBV) infection is a major global health problems leading to severe liver disease such 
as cirrhosis and hepatocellular carcinoma (HCC). HBV is a circular, partly double-stranded DNA virus with various 
serological markers: hepatitis B surface antigen (HBsAg) and anti-HBs, anti-HBc IgM and IgG, and hepatitis B e 
antigen (HBeAg) and anti-HBe. It is transmitted by sexual, parenteral and vertical route. One significant method to 
diminish the burden of this disease is timely diagnosis of acute, chronic and occult cases of HBV. First step of HBV 
diagnosis is achieved by using serological markers for detecting antigens and antibodies. In order to verify first step 
of diagnosis, to quantify viral load and to identify genotypes, quantitative or qualitative molecular tests are used. In 
this article, the serological and molecular tests for diagnosis of HBV infection will be reviewed.
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Introduction
Hepatitis B virus (HBV) belongs to the Hepadnaviridae 
family. It shows a diameter of 30–42 nm and consists of 
outer lipid envelope containing hepatitis B surface antigen 
(HBsAg) and an icosahedral capsid core composed of 
protein (1). Viral capsid bears viral genome and DNA 
polymerase that has reverse transcriptase activity. HBV 
genome comprise a circular, partly double-stranded DNA 
and has four open reading frames overlapped: (I) S that 
encodes for surface proteins (HBsAg); (II) pre-C/C for 
hepatitis B e antigen (HBeAg) and core protein (HBcAg); 
(III) P for polymerase including reverse transcriptase; 
(IV) X that encodes for a transcriptional transactivator 
factor (HBxAg) (2). The covalently closed circular DNA 
(cccDNA) is the transcriptional template of HBV and stays 
inside the hepatocyte nucleus as a mini-chromosome (3). 
Reverse transcriptase involved in the replication of HBV is 
error susceptible, thus the mutation rate is high, similarly 
observed in retroviruses and RNA viruses (4,5). 
HBV infection is responsible for the most of chronic 
liver diseases worldwide and is transmitted through 
parenteral, sexual and vertical route. About 240 million 
people are chronically infected by HBV, so have the risk of 
developing of liver cirrhosis and hepatocellular carcinoma 
(HCC). According to HBsAg prevalence, HBV endemicity 
is divided into three categories; high, intermediate, low. 
China, South East Asia, Indonesia, and sub-Saharan Africa 
are regarded as highly endemic areas because chronic HBV 
infection is reported in more than 8% of the population (6). 
Intermediate areas show chronic HBV infection rate 
between 2% and 7% of population, and include South 
America, South West Asia, Eastern and Southern Europe. 
Developed countries, such as North America and Western 
Europe are grouped as low endemic regions; in these areas, 
HBV prevalence rates range from 0.5% to 2%.
Along with active anti-HBV vaccination, one significant 
method to diminish the burden of this disease is the 
diagnosis of acute, chronic and occult HBV infection. In 
this article, the serological and molecular diagnosis of HBV 
will be reviewed.
Serological markers for HBV infection
Serological markers for HBV infection consist of HBsAg, 
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anti-HBs, HBeAg, anti-HBe, and anti-HBc IgM and IgG. 
The identification of serological markers allows: to identify 
patients with HBV infection; to elucidate the natural course 
of chronic hepatitis B (CHB); to assess the clinical phases of 
infection; and to monitor antiviral therapy (7). 
HBsAg is the serological hallmark of HBV infection. 
After an acute exposure to HBV, HBsAg appears in serum 
within 1 to 10 weeks. Persistence of this marker for more 
than 6 months implies chronic HBV infection (8). Several 
studies have reported the association between transcription 
activity of cccDNA in the liver and serum HBsAg levels 
(9-11). Differences in the serum HBsAg levels during the 
different phases of infection indicate the distribution of 
cccDNA during the respective phases of the disease. The 
serum HBsAg titers are higher in patients with HBeAg-
positive CHB than in HBeAg-negative CHB (10-12). 
Monitoring of quantitative HBsAg levels predicts treatment 
response to interferon and disease progression in HBeAg-
negative CHB patients with normal serum alanine 
aminotransferase levels (13,14).
Anti-HBs is known as a neutralizing antibody, and 
confers long-term immunity (15). In patients with acquired 
immunity through vaccination, anti-HBs is the only 
serological marker detected in serum. In the past HBV 
infection, it is present in concurrence with anti-HBc IgG. 
Occasionally, the simultaneous appearance of HBsAg 
and anti-HBs has been reported in patients with HBsAg 
positive (16). In most cases, anti-HBs antibodies are unable 
to neutralize the circulating viruses, thus these patients are 
regarded as carriers of HBV.
In the past, HBeAg and anti-HBe had been used to 
know infectivity and viral replication, but their use for 
this purpose has mostly been replaced by HBV DNA 
assay. HBeAg to anti-HBe seroconversion is related to 
the remission of hepatic disease (17), however, active 
viral replication is sustained in some patients with HBe 
seroconversion due to mutations in the pre-core and core 
region that inhibit or decrease the production of HBeAg (8).
HBcAg is  an intracellular presence in infected 
hepatocyte, thus it is not identified in the serum. During 
acute infection, anti-HBc IgM and IgG emerges 1–2 weeks 
after the presence of HBsAg along with raised serum 
aminotransferase and symptoms. After 6 months of acute 
infection, anti-HBc IgM wears off. Anti-HBc IgG continues 
to detect in both patients with resolved HBV infection and 
CHB. Some HBsAg-negative individuals are positive for 
anti-HBc IgG without anti-HBs, in this situation, it should 
be considered isolated anti-HBc positive. It can be seen in 
three conditions. First, it can be predominantly seen as IgM 
class during the window period of acute phase. Second, 
after acute infection had ended, anti-HBs has decreased 
below the cutoff level of detection. Third, after several 
years of chronic HBV infection, HBsAg has diminished 
to undetectable levels. If the result of serological markers 
shows isolated anti-HBc positive, anti-HBc IgM should be 
checked in order to assess the possibility of recent HBV 
exposure. HBV DNA assays should be tested in chronic 
liver disease patients to find out occult HBV infection 
characterized by existence of detectable HBV DNA without 
serum HBsAg (18).
Molecular methods for HBV infection
HBV DNA is a direct measurement of the viral load, which 
reveals the replication activity of the virus. It is detectable at 
the early stage of infection (1 month after HBV infection) 
and increases up to peak level (more than 108 copies/mL) 
approximately 3 months after the exposure to HBV and 
then gradually diminishes in chronic infection or disappears 
at the recovery from HBV infection.
As the prevalence of serologically negative HBV 
infection (HBeAg-negative CHB and occult HBV infection) 
has increased, HBV-DNA detection has obtained more 
awareness in clinical medicine (19). The detection of 
HBV DNA is a reliable marker of replication activity, and 
higher titers of HBV DNA are related to the more rapid 
disease progression and higher incidence of HCC (20). 
Furthermore, HBV DNA testing is useful in routine clinical 
setting to determine patients who need antiviral therapy and 
monitor them for suitable treatment (21). 
There are two principles of techniques to identify and 
quantify HBV DNA: signal amplification such as hybrid 
capture and branched DNA technology; target amplification 
such as polymerase chain reaction (PCR) (19,22). Real-time 
PCR can detect wide dynamic range of viral load (lower 
range, 10–15 IU/mL; upper range, 107–108 IU/mL). For 
this reason, it has come to be the standard method to detect 
and quantify HBV DNA in clinical setting. Furthermore, 
it can be fully automated and does not generate carry-over 
contamination (23). Table 1 displays the comparison of 
assays for quantitative measurement of HBV DNA.
HBV genotyping
HBV has a high genetic heterogeneity because it reproduces 
via a reverse transcriptase that has insufficient proofreading 
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capability. According to the sequence divergence, HBV 
can be divided into ten genotypes, labelled A–J: they have 
distinct geographic distribution (24). Genotype B and C are 
restricted to Oceania and Asia, whereas genotype A and D 
are omnipresent but most common in Africa and Europe (25). 
Genotype I is unusual and can be observed in Vietnam, 
Laos, India and China, while genotype J has been reported 
in Japan and Ryukyu (26,27). Other genotypes such as E, F, 
G, and H are also occasionally found in Asia.
Evidences increasingly suggest that the HBV genotyping 
is significant to predict HBV disease progression and 
determine appropriate antiviral therapy. Acute infection 
with genotypes A and D leads to higher rate of chronicity 
than genotypes B and C (28-30). Genotype C generally is 
considered as a risk factor for perinatal infection (31) and 
related to severe liver disease, including cirrhosis and HCC 
(32-34). In the interferon therapy, patients with genotypes A 
and B have better treatment response than genotypes C and 
D (35). Recent studies reported that patients infected with 
genotype B or C had a lower opportunity to gain serological 
response to tenofovir (36,37). 
HBV genotyping can be confirmed using diverse methods: 
reverse hybridization, genotype-specific PCR assays, 
real-time PCR, restriction fragment-length polymorphism, 
sequence analysis, microarray (DNAChip) and fluorescence 
polarization assay (38). The characteristics of variable HBV 
genotyping methods are presented on Table 2. 
Diagnosis of hepatitis B infection
Acute hepatitis B is a clinical diagnosis identified 
by the detection of HBsAg, symptoms, high serum 
aminotransferases. Usually anti-HBc IgM can be detected 
and HBV DNA is present. HBeAg can also be identified 
in most acute phase of infections, but has little clinical 
importance. The diagnosis of chronic infection is based on 
the persistence of HBsAg for more than 6 months. Patients 
with chronic HBV infection are commonly diagnosed by 
laboratory means but not by clinical presentations. Past 
HBV infection is defined by the coexistence of anti-HBs 
Table 2 Methods of HBV genotyping
Methods Advantages Disadvantages References
RFLP Easily done, low cost, simple, rapid Low sensitivity for typing 
samples with low HBV
(19,39)
Reverse hybridization High sensitivity, automated systems Relatively high cost (40,41)
Genotype specific PCR High sensitivity, automated systems, easy to perform, 
suitable for detecting mixed genotype infections
High cost (41)
Sequence analysis Gold standard method for genotyping, identification of 
patients infected with recombinant genotypes
Time consuming, technically 
demanded
(41)
HBV, hepatitis B virus; RFLP, restriction fragment length polypmorphism; PCR, polymerase chain reaction.
Table 1 Comparison of quantitative methods for HBV DNA
Methods Commercial assay name Manufacturer
Measurable 
range (IU/mL)
Limit of detection (IU/mL) 
(using WHO HBV standard)
Semi-automated 
qPCR
COBAS AmpliPrep/COBAS 
TaqMan HBV Test v2.0
Roche Molecular System, 
California, United States
20–1.7× 107 20
Semi-automated 
real-time PCR
COBAS TaqMan HBV Test for 
use with high pure system
Roche Molecular System, 
California, United States
29–1.1×107 6
Automated  
real-time PCR
Abbott RealTime HBV Abbott Diagnostic, Chicago,  
United States
10–1×109 10
Branched DNA VERSANT HBV 3.0 Assay Siemens Healthcare, United States 2,000–1×108 2,000
WHO, World Health Organization; HBV, hepatitis B virus; PCR, polymerase chain reaction; qPCR, quantitative PCR.
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and IgG anti-HBc. 
Occult HBV infection is defined by persistence of low 
level of intrahepatic HBV DNA without detectable HBsAg 
(42,43). It is a serological situation defined by the presence 
of isolated anti-HBc with the absence of HBsAg and anti-
HBs antibody (44,45). The detection of HBV DNA in 
the liver is the gold standard of diagnosis for occult HBV 
infection, since cccDNA remains in the hepatocytes and 
HBV DNA is occasionally identified in the liver but not in 
the serum. However, gaining hepatic HBV DNA is difficult 
in clinical setting since the procedure is invasive. Real-time 
PCR for serum HBV DNA detection have been shown 
with adequate sensitivity to identify occult HBV infection 
in many cases; thus, HBV DNA testing is widely used to 
diagnose occult HBV infection (43). 
Occult HBV infection has some clinical importance. 
First, it can be transmitted via transfusion, solid organ 
transplantation including orthotopic liver transplantation 
(46,47), or hemodialysis (48,49). Second, reactivation of HBV 
infection may occur in patients receiving chemotherapy or 
immunocompromised state (50-52). Third, it may accelerate 
liver injury and lead to hepatic fibrosis in patients with 
chronic liver disease including chronic hepatitis C infection 
(53-55). Forth, it appears to be a risk factor for HCC by its 
carcinogenic effect and by leading to continuous hepatic 
inflammation and fibrosis (56-58). 
Tests for occult HBV infection are considered in the 
following conditions: in patients with cryptogenic liver 
disease, especially when having anti-HBc in serum; in 
patients considering immunosuppression therapy or 
chemotherapy; and in solid organ transplantation donors, 
due to the possibilities for transmission (59). 
Conclusions
In this article, we aimed to give informations about HBV 
serological and molecular diagnosis. First step of HBV 
diagnosis is achieved by using serological markers for detecting 
antigens and antibodies against this virus. In order to verify 
first step of diagnosis, to quantify viral load and to identify 
genotypes, qualitative or quantitative molecular tests are used. 
Diagnosis of HBV infection is an important tool to determine 
acute, chronic and occult cases of infection in order to establish 
preventive remedies and to initiate antiviral treatment.
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